Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune liver diseases

D J Bylund1, J McHutchison

  • 1Department of Gastroenterology, Scripp's Clinic and Research Foundation, La Jolla, California, USA.

Clinics in Laboratory Medicine
|October 8, 1997
PubMed
Summary

Autoantibodies are key diagnostic markers for autoimmune liver diseases (AiLD), though their exact cause remains unclear. Cell-mediated immunity also plays a crucial role in liver injury in these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

Journal of viral hepatitis·2008
Same author

Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.

Journal of viral hepatitis·2005
Same author

Response to article by Formann et Al. (2003).

Journal of viral hepatitis·2004
Same author

Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients.

Expert opinion on pharmacotherapy·2001
Same author

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

Journal of hepatology·2001
Same author

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

Hepatology (Baltimore, Md.)·2000

Area of Science:

  • Immunology
  • Hepatology
  • Autoimmunity

Background:

  • Autoimmune liver diseases (AiLD) are characterized by autoantibodies and humoral immune abnormalities.
  • The precise etiology and pathogenesis of AiLD are not fully understood.
  • Cell-mediated immune mechanisms are increasingly recognized as critical contributors to tissue injury in AiLD.

Purpose of the Study:

  • To review the role of autoantibodies as diagnostic markers in AiLD.
  • To discuss the diagnostic utility of specific autoantibodies like AMA, ANA, SMA, and LKM.
  • To highlight the importance of standardized testing methods for autoantibodies in AiLD diagnosis.

Main Methods:

  • Review of literature on autoantibody detection in autoimmune liver diseases.
  • Discussion of immunofluorescence assays (IIFM) for ANA, SMA, and LKM detection.
  • Mention of enzyme-linked immunosorbent assays (ELISA) for AMA (anti-M2) quantification.

Main Results:

  • Antimitochondrial antibodies (AMA) are the most sensitive and specific marker for primary biliary cholangitis (PBC).
  • Antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and liver kidney microsomal antibodies (LKM) characterize autoimmune hepatitis (AiH).
  • IIFMs using Hep-2 cells and rodent tissues are common methods for detecting these autoantibodies.

Conclusions:

  • Serum autoantibodies are valuable diagnostic markers for AiLD.
  • Standardization of autoantibody testing through methods like ELISA will improve diagnostic accuracy.
  • Understanding both humoral and cell-mediated immunity is essential for managing AiLD.

Related Experiment Videos